Mobileye (MBLY) Q4 2024 Earnings Call Transcript

Mobileye reported Q4 operating margin of 21%, up nearly 5 percentage points sequentially, and full-year operating cash flow of $400 million, roughly double non-GAAP net income. Management guided 2025 revenue to a midpoint of $1.75 billion, implying about 6% growth, with adjusted operating income of $217 million and gross margin expected to improve 150 bps. The outlook remains conservative, with EyeQ volume guided at 32 million to 34 million units and SuperVision volumes in the low 20,000s amid continued uncertainty in OEM production and China demand.

Analysis

The key incremental takeaway is that MBLY is turning the current lull in OEM adoption into a balance-sheet and margin reset, not a growth reset. The market is likely underweighting how much of the 2025 setup is self-help: lower SuperVision mix, disciplined OpEx, and working-capital release can keep cash generation ahead of earnings even if top-line execution is only mid-single digits. That matters because it reduces financing/rollover risk and gives management more time to wait out OEM decision cycles without needing to prove an imminent step-function in revenue.

The bigger strategic signal is that the real option value is in 2026-2028 program content, not the 2025 numbers. Management is effectively telling us that the near-term debate is not whether Mobileye wins technically, but whether OEMs can operationalize higher autonomy fast enough; that shifts the competitive frame away from “best algorithm wins” toward “who can ship across multiple architectures at acceptable cost and liability.” If that is right, the main second-order beneficiary is not just MBLY but the Tier 1 ecosystem that can piggyback on a Mobileye-led rollout, while pure in-house efforts remain capital intensive and slow to industrialize.

The contrarian miss is that consensus is still pricing MBLY like a cyclical ADAS supplier when management is describing an embedded platform business with delayed but potentially sticky attach rates. The near-term China conservatism likely caps upside in the next couple quarters, but it also creates room for beats if domestic OEM demand stabilizes or if any of the named Western program timelines firm up. The risk is that the 2027-2028 cadence slips again; however, the call suggests the more plausible failure mode is timing pushout, not displacement by competitors or in-house systems.

Key Decisions for Investors

• Long MBLY on pullbacks into the next 2-4 weeks; use the conservative guide as a setup for a beat/raise pattern later in 2025. Risk/reward skews favorably if cash flow remains > earnings and any OEM nominations land, with downside limited by balance-sheet strength and valuation support.
• Pair trade: long MBLY / short IHS or broader auto-supply proxy over the next 3-6 months. MBLY has a cleaner AI/software content ramp and less direct exposure to powertrain cyclicality, while the short leg captures the market’s tendency to over-penalize automotive data names for macro noise.
• Buy MBLY Jan-2026 calls or call spreads to express a 12-18 month re-rating on 2026 program visibility. The thesis is that options premium is cheaper than stock if the market is still discounting nomination timing risk rather than technical execution.
• Tactically hedge with a short TSLA overlay or TSLA puts if you are long MBLY beta-neutral. The call reinforces that Tesla is more of a forcing function than a direct threat; if Tesla-driven urgency increases OEM spending, MBLY benefits, but TSLA also remains the most visible competitive narrative pressure point.
• Monitor LYFT only as a secondary beneficiary of revived robotaxi urgency; if Mobileye-led partnerships accelerate, LYFT gets incremental optionality. Prefer to wait for proof of partner alignment before sizing any long.